CORDIS - Resultados de investigaciones de la UE
CORDIS

Biomarkers in Atopic Dermatitis and Psoriasis

Descripción del proyecto

Sistemas de medicina predictiva para la gestión de la dermatitis atópica y la psoriasis

El objetivo del proyecto BIOMAP, financiado con fondos europeos, es ofrecer un modelo de medicina predictiva de la dermatitis atópica y la psoriasis basado en perfiles moleculares y clínicos. El consorcio identificará factores determinantes clínicos de resultados relevantes, elucidará los mecanismos de la enfermedad y aportará biomarcadores para predecir las trayectorias patológicas y la respuesta al tratamiento a fin de utilizarlos en el desarrollo de fármacos y la práctica clínica. BIOMAP creará una muestra biológica y recursos de datos a una escala y un detalle sin precedentes, que serán accesibles a través de un portal central de análisis de datos. Este recurso apoyará los análisis en epidemiología, elaboración de perfiles moleculares, biología de la piel y modelización matemática para definir endotipos de fármacos y enfermedades, así como factores esenciales relativos al medio ambiente y al estilo de vida.

Objetivo

Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
Aportación neta de la UEn
€ 1 478 387,00
Dirección
OLSHAUSENSTRASSE 40
24118 Kiel
Alemania

Ver en el mapa

Región
Schleswig-Holstein Schleswig-Holstein Kiel, Kreisfreie Stadt
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 2 332 141,00

Participantes (35)